The research aims to deepen understanding of schizophrenia’s biological basis, aiding early detection, personalized treatment, and improved quality of life. By integrating genomics, proteomics, neuroimaging, and cognitive assessments, it seeks to identify biomarkers for risk prediction, diagnosis, and prognosis. Additionally, it explores the impact of COVID-19 on schizophrenia progression, addressing current public health concerns. Ultimately, the findings hold promise for developing novel diagnostic tools and targeted interventions, benefiting individuals affected by this debilitating disorder and advancing public health outcomes.
